ApoB, which constitutes a composite of all major atherogenic lipoproteins, inclusive of LDL, VLDL, IDL, remnant particles and Lp(a) would be a better therapeutic target to minimize ASCVD risk. The gene discussed is LPA; the disease is atherosclerosis.